<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16066">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897726</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1402-01</org_study_id>
    <nct_id>NCT02897726</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Pharmacokinetics of NVP-1402</brief_title>
  <official_title>A Clinical Trial to Evaluate the Pharmacokinetics and Safety of NVP-1402 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the safety and pharmacokinetics of
      NVP-1402 and NVP-1402R in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as randomized, open-label, active-controlled and crossover assignment
      for evaluate and compare the safety and pharmacokinetics of NVP-1402 and NVP-1402R in
      healthy male subjects. The safety assessed through adverse events up to 17 days after
      administration. Additional variables (ECGs, laboratory test, vital signs, so on) will also
      be recorded and assessed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 24, 2017</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: Cmax</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasm: AUClast</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: AUCinf</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: Tmax</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: t1/2</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NVP-1402</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-1402 was administered once a day for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1402R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator was administered twice a day for 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1402</intervention_name>
    <description>Oral</description>
    <arm_group_label>NVP-1402</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1402R</intervention_name>
    <description>Oral</description>
    <arm_group_label>NVP-1402R</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  No history of clinically significant medical disorder

          -  Capable of consent to participate in the study

        Exclusion Criteria:

          -  History of hypersensitive reactions to study drug or other related drugs

          -  Any significant abnormality found during screening

          -  Any significant medical history

          -  History of alcohol abuse, smoking continuously

          -  History of drug abuse

          -  Clinically significant surgery within 4 weeks prior to administration of the study
             drug

          -  Participation in another clinical trial within 3 months prior to administration of
             the study drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Ran Yoon, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>September 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
